Priya Balasubramanian

Priya Balasubramanian has a diverse work experience in the pharmaceutical and biotechnology industry. Priya currently serves as the Head of Analytical Development and Quality Control for CTMC, a joint venture between Resilience and MD Anderson Cancer Center. Prior to this, they worked at MD Anderson Cancer Center as the Head of Analytical and Quality Control.

Before joining MD Anderson, Priya held various roles at Ziopharm Oncology, including Director of CMC Development & QC, Technical Operations, Director of Analytical Development, and Associate Director of Analytical Development, all within the Cell Therapy Technical Operations department.

Priya also worked at Bellicum Pharmaceuticals, Inc. as a Senior Manager and Senior Scientist in Assay Development, and as an Assay Development Scientist at ApoCell, Inc. Additionally, Priya gained valuable experience at Leidos Biomedical Research, Inc., where they served as a Scientist I and Post Doctoral Fellow, working on various projects related to the development and validation of biomarker assays.

Priya'searlier experience includes serving as a Graduate Research Associate at The Ohio State University, where they worked on a wide range of laboratory research projects and also worked as a Laboratory Services Coordinator, assisting in experiments, testing samples, and operating various analytical instruments.

Overall, Priya Balasubramanian's work experience demonstrates their expertise in analytical development, quality control, CMC development, and assay development within the pharmaceutical and biotechnology industry.

Priya Balasubramanian obtained their B.Tech degree in Chemical Engineering from Anna University, where they studied from 2001 to 2005. Priya then pursued their Ph.D. in Chemical and Biomolecular Engineering at The Ohio State University from 2005 to 2010.

In addition to their formal education, Priya also obtained several certifications. In 2007, they became a BD FACS Aria Operator certified by BD Biosciences. In 2010, they obtained a certification in Poly (ADP-Ribose) (PAR) Immunoassay from NCI's Division of Cancer Treatment and Diagnosis. Priya further enhanced their skills with a certification in CellSearch Interpretation Training from Veridex, LLC in 2011. The same year, they earned another certification, this time in gamma-H2AX Immunofluorescent Assay for Tumor Biopsies from NCI's Division of Cancer Treatment and Diagnosis. Finally, in 2012, they acquired a gH2AX Immunofluorescence Assay for Circulating Tumor Cells Using the CellSearch System certification from NCI's Division of Cancer Treatment and Diagnosis.